Metformin
Treatment for Diabetes Mellitus Type 2
Typical Dosage: 500-2550 mg daily
Effectiveness
88%
Safety Score
65%
Clinical Trials
1,523
Participants
2M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
500-2550 mg daily
Time to Effect
1-2 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10000(Treat 10000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40
Monitoring:$425
Side Effect Mgmt:$50
Total Annual:$515
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
0.75
Outcome-Based Costs
Cost per Responder
$686.67
Cost per Remission
$7,357.14
Metformin Outcomes
for Diabetes Mellitus Type 2
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Remission Rate
+7%
Common Side Effects
Diarrhea
+35%
Nausea/Vomiting
+15%
Abdominal discomfort
+18%
Lactic acidosis
+0.1%
B12 deficiency
+7%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
13 completed trials for Metformin in Diabetes Mellitus Type 2
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
NCT02565368COMPLETEDPHASE1
26 participants
INTERVENTIONAL
Jeonju, South Korea
Started: Jul 1, 2015
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
NCT02685774COMPLETEDPHASE1
26 participants
INTERVENTIONAL
Jeonju, South Korea
Started: Feb 1, 2016
Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
NCT00577590COMPLETEDNA
78 participants
INTERVENTIONAL
St Louis, United States
Started: Oct 1, 2003
A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
NCT04218734COMPLETEDPHASE3
214 participants
INTERVENTIONAL
Beijing, China
Started: Jan 14, 2020
Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
NCT03604419COMPLETEDPHASE2
214 participants
INTERVENTIONAL
Miami, United States
Started: Jun 13, 2018
Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy
NCT01972724COMPLETEDPHASE4
114 participants
INTERVENTIONAL
Chagwon, South Korea +8 more
Started: Dec 16, 2013
Bioequivalence Study for Acarbose / Metformin FDC
NCT01728740COMPLETEDPHASE1
40 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 1, 2012
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
NCT01505426COMPLETEDPHASE3
171 participants
INTERVENTIONAL
Busan, South Korea +11 more
Started: Nov 28, 2011
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers
NCT02627027COMPLETEDPHASE1
26 participants
INTERVENTIONAL
Jeonju, South Korea
Started: Aug 1, 2015
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
NCT01068730COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Austin, United States
Started: Feb 1, 2010
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
NCT02151461COMPLETEDPHASE2
96 participants
INTERVENTIONAL
Chino, United States +8 more
Started: Jul 1, 2014
An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients
NCT02435277COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Chino, United States +8 more
Started: Oct 1, 2014
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
NCT02068443COMPLETEDPHASE3
374 participants
INTERVENTIONAL
Nagoya, Japan +26 more
Started: Feb 1, 2014
Showing 20 of 1539 total trials